1. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors;Ceribelli;Proc Natl Acad Sci USA,2014
2. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs;Boi;Clin Cancer Res,2015
3. The mechanisms behind the therapeutic activity of BET bromodomain inhibition;Shi;Mol Cell,2014
4. Selective inhibition of tumor oncogenes by disruption of super-enhancers;Lovén;Cell,2013
5. Bromodomains as therapeutic targets;Muller;Expert Rev Mol Med,2011